Aytu Biopharma, Inc (AYTU) — SEC Filings
Aytu Biopharma, Inc (AYTU) — 28 SEC filings. Latest: 8-K (Dec 10, 2025). Includes 12 8-K, 6 10-Q, 3 DEF 14A.
View Aytu Biopharma, Inc on SEC EDGAR
Overview
Aytu Biopharma, Inc (AYTU) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: AYTU BioPharma, Inc. reported a net income of $1.965 million for the three months ended September 30, 2025, an increase from $1.474 million in the same period of 2024. Despite this, net revenue decreased to $13.888 million from $16.574 million year-over-year, representing a 16.3% decline. The compan
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 2 bearish, 24 neutral, 2 mixed. The dominant filing sentiment for Aytu Biopharma, Inc is neutral.
Filing Type Overview
Aytu Biopharma, Inc (AYTU) has filed 12 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 1 S-1/A, 1 S-1, 2 SC 13G/A, 1 SC 13D/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of AYTU's 24 recent filings, 3 were flagged as high-risk, 12 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $13.888M |
| Net Income | $1.965M |
| EPS | N/A |
| Debt-to-Equity | 1.55 |
| Cash Position | $32.630M |
| Operating Margin | -11.4% |
| Total Assets | $124.988M |
| Total Debt | $26.777M |
Key Executives
- Joshua R. Disbrow
- John A. Donofrio, Jr.
- Jarrett T. Disbrow
- Anthony W. Epps
- Joshua B. Erekson
- David Danovitch
- Aaron Schleicher
- Daniel Mack
- Wilmot B. Harkey
- Taki Vasilakis
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies often rely on a few key products for revenue, making pipeline success and commercialization critical. The market for treatments for Major Depressive Disorder is competitive, with ongoing innovation and demand for effective therapies.
Top Tags
Biopharma (6) · filing (5) · 10-Q (5) · financials (4) · Pharmaceuticals (3) · SEC Filing (3) · warrants (3) · AYTU (3) · Proxy Statement (2) · Director Election (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Revenue | $13.888M | Decreased from $16.574M in Q3 2024, a 16.3% decline. |
| Net Income | $1.965M | Increased from $1.474M in Q3 2024, primarily due to warrant gains. |
| Derivative Warrant Liabilities Gain | $3.784M | Significant non-operating gain contributing to net income. |
| Cash and Cash Equivalents | $32.630M | Increased from $30.952M at June 30, 2025. |
| Common Stock Outstanding | 10,188,208 | As of November 1, 2025. |
| Total Operating Expenses | $10.690M | Decreased from $12.915M in Q3 2024. |
| Shares of common stock outstanding | 10,188,208 | Entitled to vote as of October 13, 2025 record date |
| Number of directors to be elected | 5 | Current and proposed number of directors on the Board |
| Date of Annual Meeting | December 10, 2025 | When stockholders will vote on proposals |
| Record Date | October 13, 2025 | Determines stockholders eligible to vote at the Annual Meeting |
| Proxy voting deadline | 11:59 p.m. Eastern time on December 9, 2025 | Last time to submit votes via Internet or telephone |
| Quorum requirement | 33.3% | Percentage of outstanding shares needed for Annual Meeting to conduct business |
| Net Loss | $13.6 million | for the year ended June 30, 2025, indicating continued unprofitability. |
| Accumulated Deficit | $333.5 million | as of June 30, 2025, highlighting significant historical losses. |
| ADHD Portfolio Net Revenue | $57.6 million | second highest in company history for fiscal 2025, demonstrating strong product performance. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Aytu Biopharma, Inc (AYTU)?
Aytu Biopharma, Inc has 28 recent SEC filings from Feb 2024 to Dec 2025, including 12 8-K, 6 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AYTU filings?
Across 28 filings, the sentiment breakdown is: 2 bearish, 24 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Aytu Biopharma, Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Aytu Biopharma, Inc (AYTU) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Aytu Biopharma, Inc?
Key financial highlights from Aytu Biopharma, Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AYTU?
The investment thesis for AYTU includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Aytu Biopharma, Inc?
Key executives identified across Aytu Biopharma, Inc's filings include Joshua R. Disbrow, John A. Donofrio, Jr., Jarrett T. Disbrow, Anthony W. Epps, Joshua B. Erekson and 5 others.
What are the main risk factors for Aytu Biopharma, Inc stock?
Of AYTU's 24 assessed filings, 3 were flagged high-risk, 12 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Aytu Biopharma, Inc?
Forward guidance and predictions for Aytu Biopharma, Inc are extracted from SEC filings as they are enriched.